A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 5, 2009, Pages 379-384

  Bonnema, Steen J ^a   Hegedüs, Laszlo ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Nodular goiter; Radioiodine; Recombinant human thyrotropin

Indexed keywords

ANALGESIC AGENT; ANTITHYROID AGENT; CORTICOSTEROID DERIVATIVE; IODINE 131; LEVOTHYROXINE; PLACEBO; RECOMBINANT THYROTROPIN; THYROID PEROXIDASE ANTIBODY;

CHRONOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECOMPRESSION; DOSE RESPONSE; DRUG EFFICACY; FOLLOW UP; GRAVES DISEASE; HORMONAL REGULATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LOW DRUG DOSE; MEDICAL DECISION MAKING; MULTICENTER STUDY; NODULAR GOITER; OFF LABEL DRUG USE; RADIATION CARCINOGENESIS; RADIATION INJURY; RADIOISOTOPE THERAPY; RESPIRATORY FUNCTION; REVIEW; SWELLING; THYROID CANCER; THYROID SCINTISCANNING; THYROID SWELLING; THYROID WEIGHT; THYROIDITIS; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; GOITER, NODULAR; HUMANS; IODINE RADIOISOTOPES; RADIATION-SENSITIZING AGENTS; RECOMBINANT PROTEINS; THYROTROPIN;

EID: 69449097107     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32832ff2e1     Document Type: Review

References (55)

1. Hegedüs L, Bonnema SJ, Bennedbæk FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24:102-132. (Pubitemid 36223282)
2. Vejbjerg P, Knudsen N, Perrild H, et al. Effect of a mandatory iodization program on thyroid gland volume based on individuals' age, gender, and preceding severity of dietary iodine deficiency: a prospective, population-based study. J Clin Endocrinol Metab 2007; 92:1397-1401. (Pubitemid 46556416)
3. Jarløv AE, Hegedüs L, Gjørup T, Hansen JE. Accuracy of the clinical assessment of thyroid size. Dan Med Bull 1991; 38:87-89.
4. Bonnema SJ. Upper airway obstruction due to goiter: an overlooked problem! J Postgrad Med 2008; 54:82-83.
5. Gittoes NJ, Miller MR, Daykin J, et al. Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. Br Med J 1996; 312:484. (Pubitemid 26061241)
6. Pradeep PV, Tiwari P, Mishra A, et al. Pulmonary function profile in patients with benign goiters without symptoms of respiratory compromise and the early effect of thyroidectomy. J Postgrad Med 2008; 54:98-101. (Pubitemid 351724191)
7. Bonnema SJ, Bennedbæk FN, Wiersinga WM, Hegedüs L. Management of the nontoxic multinodular goitre: a European questionnaire study. Clin Endocrinol (Oxf) 2000; 53:5-12. (Pubitemid 30646121)
8. Bonnema SJ, Bennedbæk FN, Ladenson PW, Hegedüs L. Management of the nontoxic multinodular goiter: a North American survey. J Clin Endocrinol Metab 2002; 87:112-117. (Pubitemid 34084679)
9. Bhagat MC, Dhaliwal SS, Bonnema SJ, et al. Differences between endocrine surgeons and endocrinologists in the management of nontoxic multinodular goitre. Br J Surg 2003; 90:1103-1112.
10. Bonnema SJ, Nielsen VE, Hegedüs L. Long-term effects of radioiodine on thyroid function, size and patient satisfaction in nontoxic diffuse goitre. Eur J Endocrinol 2004; 150:439-445. (Pubitemid 38584693)
11. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. J Am Med Assoc 2004; 291:228-238. (Pubitemid 38082818)
12. Wesche MF, Tiel-Van Buul MM, Lips P, et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001; 86:998-1005. (Pubitemid 32322972)
13. Fast S, Bonnema SJ, Hegedüs L. The majority of Danish nontoxic goitre patients are ineligible for Levothyroxine suppressive therapy. Clin Endocrinol (Oxf) 2008; 69:653-658.
14. Hegedüs L, Nygaard B, Hansen JM. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J Clin Endocrinol Metab 1999; 84:756-760.
15. al Suliman NN, Ryttov NF, Qvist N, et al. Experience in a specialist thyroid surgery unit: a demographic study, surgical complications, and outcome. Eur J Surg 1997; 163:13-20.
16. Watt T, Grønvold M, Rasmussen AK, et al. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol 2006; 154:501-510.
17. Dietlein M, Lauterbach KW, Schicha H. Treatment of toxic nodular goitres: comparative costing of radioiodine therapy and surgery. Exp Clin Endocrinol Diabetes 1998; 106 (Suppl 4):S66-S70. (Pubitemid 28537592)
18. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999; 84:3636-3641. (Pubitemid 30645217)
19. Huysmans DA, Hermus AR, Corstens FH, et al. Large, compressive goiters treated with radioiodine. Ann Intern Med 1994; 121:757-762.
20. Le Moli R, Wesche MF, Tiel-Van Buul MM, Wiersinga WM. Determinants of long-term outcome of radioiodine therapy of sporadic non toxic goitre. Clin Endocrinol (Oxf) 1999; 50:783-789. (Pubitemid 29284513)
21. Nygaard B, Hegedüs L, Gervil M, et al. Radioiodine treatment of multinodular nontoxic goitre. Br Med J 1993; 307:828-832. (Pubitemid 23281746)
22. Nygaard B, Hegedüs L, Ulriksen P, et al. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med 1999; 159:1364-1368. (Pubitemid 29293600)
23. Bonnema SJ, Knudsen DU, Bertelsen H, et al. Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging. Thyroid 2002; 12:313-317. (Pubitemid 34438935)
24. Bonnema SJ, Nielsen VE, Boel-Jørgensen H, et al. Improvement of goiter volume reduction after 0.3mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 2007; 92:3424-3428. (Pubitemid 47435314)
25. Jarløv AE, Hegedüs L, Kristensen LØ, et al. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) 1995; 43:325-329.
26. Nygaard B, Knudsen JH, Hegedüs L, et al. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 1997; 82:2926-2930. (Pubitemid 27385650)
27. Nygaard B, Metcalfe RA, Phipps J, et al. Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of nontoxic goiter. J Endocrinol Invest 1999; 22:481-485. (Pubitemid 29355567)
28. Nielsen VE, Bonnema SJ, Boel-Jørgensen H, et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 2006; 166:1476-1482. (Pubitemid 44125866)
29. Cohen O, Ilany J, Hoffman C, et al. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur J Endocrinol 2006; 154:243-252. (Pubitemid 43308826)
30. Albino CC, Mesa CO Jr, Olandoski M, et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab 2005; 90:2775-2780. (Pubitemid 40686323)
31. Silva MN, Rubio IG, Romao R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf) 2004; 60:300-308. (Pubitemid 38297119)
32. Nieuwlaat WA, Huysmans DA, Van Den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003; 88:3121-3129. (Pubitemid 36877482)
33. Paz-Filho GJ, Mesa-Junior CO, Olandoski M, et al. Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz J Med Biol Res 2007; 40:1661-1670.
34. Baczyk M, Junik R, Ziemnicka K, Sowinski J. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease. Nuklearmedizin 2005; 44:197-199.
35. Vej-Hansen A, Nygaard B. Iodine uptake and the effect of radioiodine treatment: status after the addition of iodine to salt. Ugeskr Laeger 2005; 167:3684-3687. (Pubitemid 41403268)
36. Fast S, Nielsen VE, Bonnema SJ, Hegedüs L. Time to reconsider nonsurgical therapy of benign nontoxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol 2009; 160:517-528. A comprehensive review of rhTSH-augmented 131I therapy of patients with a multinodular goiter.
37. 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab 2005; 90:79-83.
38. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab 2001; 86:5330-5336. (Pubitemid 33070255)
39. 131I administration.
40. Giusti M, Cappi C, Santaniello B, et al. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter. Minerva Endocrinol 2006; 31:191-209.
41. Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocrine Practice 2003; 9:204-209.
42. Cubas ER, Paz-Filho GJ, Olandoski M, et al. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int J Clin Pract 2009; 63:583-590.
43. Huysmans DA, Nieuwlaat WA, Erdtsieck RJ, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000; 85:3592-3596.
44. 131I therapy in improving inspiration.
45. Paz-Filho GJ, Mesa CO, Carvalho GA, et al. Recombinant human TSH associated with radioiodine does not have further effects on thyroid volume and function after 2 years. Clin Endocrinol (Oxf) 2008; 69:345-346.
46. Cardia MS, Rubio IG, Medeiros-Neto G. Prolonged follow-up of multinodular goitre patients treated with radioiodine preceded or not by human recombinant TSH. Clin Endocrinol (Oxf) 2006; 64:474.
47. Nygaard B, Faber J, Hegedüs L. Acute changes in thyroid volume and function following 131I therapy of multinodular goitre. Clin Endocrinol (Oxf) 1994; 41:715-718.
48. Nielsen VE, Bonnema SJ, Hegedüs L. Effects of 0.9mg recombinant human thyrotropin on thyroid size and function in normal subjects: a randomized, double-blind, cross-over trial. J Clin Endocrinol Metab 2004; 89:2242-2247. (Pubitemid 38619859)
49. Nielsen VE, Bonnema SJ, Hegedüs L. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab 2006; 91:1317-1322.
50. Fast S, Nielsen VE, Bonnema SJ, Hegedüs L. Dose-dependent acute effect of recombinant human TSH (rhTSH) on thyroid size and function. Comparison of 0.1, 0.3 and 0.9mg of rhTSH. Clin Endocrinol (Oxf) 2009. doi: 10.1111/j.1365-2265.2009.03650.x. [Epub ahead of print] Trial in healthy subjects showing that stimulation with 0.1mg rhTSH results in clinically insignificant changes of the thyroid volume and hormones.
51. Pena S, Arum S, Cross M, et al. 123I Thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab 2006; 91:506-510. (Pubitemid 43236916)
52. Torres MS, Ramirez L, Simkin PH, et al. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001; 86:1660-1664. (Pubitemid 32374920)
53. Franklyn JA, Maisonneuve P, Sheppard M, et al. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1999; 353:2111-2115. (Pubitemid 29278480)
54. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism: Cooperative Thyrotoxicosis Therapy Follow-up Study Group. J Am Med Assoc 1998; 280:347-355.
55. Nieuwlaat WA, Hermus AR, Ross HA, et al. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone. J Nucl Med 2004; 45:626-633.